172 related articles for article (PubMed ID: 1694919)
1. Mechanism of action of bucindolol in human ventricular myocardium.
Hershberger RE; Wynn JR; Sundberg L; Bristow MR
J Cardiovasc Pharmacol; 1990 Jun; 15(6):959-67. PubMed ID: 1694919
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization of chick and frog beta adrenergic receptors in primary cultures of myocardial cells.
Port JD; Debellis CC; Klein J; Peeters GA; Barry WH; Bristow MR
J Pharmacol Exp Ther; 1992 Jul; 262(1):217-24. PubMed ID: 1352549
[TBL] [Abstract][Full Text] [Related]
3. Adenylate cyclase agonist properties of CGP-12177A in brown fat: evidence for atypical beta-adrenergic receptors.
Scarpace PJ; Matheny M
Am J Physiol; 1991 Feb; 260(2 Pt 1):E226-31. PubMed ID: 1671733
[TBL] [Abstract][Full Text] [Related]
4. Bucindolol exerts agonistic activity on the propranolol-insensitive state of beta1-adrenoceptors in human myocardium.
Bundkirchen A; Brixius K; Bölck B; Schwinger RH
J Pharmacol Exp Ther; 2002 Mar; 300(3):794-801. PubMed ID: 11861783
[TBL] [Abstract][Full Text] [Related]
5. Receptor pharmacology of carvedilol in the human heart.
Bristow MR; Larrabee P; Minobe W; Roden R; Skerl L; Klein J; Handwerger D; Port JD; Müller-Beckmann B
J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S68-80. PubMed ID: 1378154
[TBL] [Abstract][Full Text] [Related]
6. Determination of beta-adrenoceptor subtype on rat isolated ventricular myocytes by use of highly selective beta-antagonists.
Kitagawa Y; Adachi-Akahane S; Nagao T
Br J Pharmacol; 1995 Sep; 116(1):1635-43. PubMed ID: 8564230
[TBL] [Abstract][Full Text] [Related]
7. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium.
Brixius K; Bundkirchen A; Bölck B; Mehlhorn U; Schwinger RH
Br J Pharmacol; 2001 Aug; 133(8):1330-8. PubMed ID: 11498519
[TBL] [Abstract][Full Text] [Related]
8. Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes.
Bristow MR; Larrabee P; Müller-Beckmann B; Minobe W; Roden R; Skerl L; Klein J; Handwerger D; Port JD
Clin Investig; 1992; 70 Suppl 1():S105-13. PubMed ID: 1350478
[TBL] [Abstract][Full Text] [Related]
9. Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium.
Maack C; Cremers B; Flesch M; Höper A; Südkamp M; Böhm M
Br J Pharmacol; 2000 Jul; 130(5):1131-9. PubMed ID: 10882399
[TBL] [Abstract][Full Text] [Related]
10. Bucindolol, a nonselective beta 1- and beta 2-adrenergic receptor antagonist, decreases beta-adrenergic receptor density in cultured embryonic chick cardiac myocyte membranes.
Asano K; Zisman LS; Yoshikawa T; Headley V; Bristow MR; Port JD
J Cardiovasc Pharmacol; 2001 Jun; 37(6):678-91. PubMed ID: 11392464
[TBL] [Abstract][Full Text] [Related]
11. Effects of celiprolol (REV 5320), a new cardioselective beta-adrenoceptor antagonist, on in vitro adenylate cyclase, alpha- and beta-adrenergic receptor binding and lipolysis.
Van Inwegen RG; Khandwala A; Weinryb I; Pruss TP; Neiss E; Sutherland CA
Arch Int Pharmacodyn Ther; 1984 Nov; 272(1):40-55. PubMed ID: 6151380
[TBL] [Abstract][Full Text] [Related]
12. Regulation of alpha and beta adrenergic receptors by triiodothyronine in cultured rat myocardial cells.
Kupfer LE; Bilezikian JP; Robinson RB
Naunyn Schmiedebergs Arch Pharmacol; 1986 Nov; 334(3):275-81. PubMed ID: 3027586
[TBL] [Abstract][Full Text] [Related]
13. Effects of xamoterol on inotropic and lusitropic properties of the human myocardium and on adenylate cyclase activity.
Böhm M; Mittmann C; Schwinger RH; Erdmann E
Am Heart J; 1990 Dec; 120(6 Pt 1):1381-92. PubMed ID: 1978979
[TBL] [Abstract][Full Text] [Related]
14. Age-related changes in beta-adrenergic neuroeffector systems in the human heart.
White M; Roden R; Minobe W; Khan MF; Larrabee P; Wollmering M; Port JD; Anderson F; Campbell D; Feldman AM
Circulation; 1994 Sep; 90(3):1225-38. PubMed ID: 8087932
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological analysis of the cardiac actions of xamoterol, a beta adrenoceptor antagonist with partial agonistic activity, in guinea pig heart: evidence for involvement of adenylate cyclase system in its cardiac stimulant actions.
Hattori Y; Sakuma I; Nakao Y; Kanno M
J Pharmacol Exp Ther; 1987 Sep; 242(3):1077-85. PubMed ID: 2888870
[TBL] [Abstract][Full Text] [Related]
16. Characterization of beta(1)-selectivity, adrenoceptor-G(s)-protein interaction and inverse agonism of nebivolol in human myocardium.
Maack C; Tyroller S; Schnabel P; Cremers B; Dabew E; Südkamp M; Böhm M
Br J Pharmacol; 2001 Apr; 132(8):1817-26. PubMed ID: 11309254
[TBL] [Abstract][Full Text] [Related]
17. Species comparison of adenosine and beta-adrenoceptors in mammalian atrial and ventricular myocardium.
Musser B; Morgan ME; Leid M; Murray TF; Linden J; Vestal RE
Eur J Pharmacol; 1993 Jul; 246(2):105-11. PubMed ID: 8397091
[TBL] [Abstract][Full Text] [Related]
18. Partial agonist activity of bucindolol is dependent on the activation state of the human beta1-adrenergic receptor.
Maack C; Böhm M; Vlaskin L; Dabew E; Lorenz K; Schäfers HJ; Lohse MJ; Engelhardt S
Circulation; 2003 Jul; 108(3):348-53. PubMed ID: 12847069
[TBL] [Abstract][Full Text] [Related]
19. Classical and atypical binding sites for beta-adrenoceptor ligands and activation of adenylyl cyclase in bovine skeletal muscle and adipose tissue membranes.
Sillence MN; Matthews ML
Br J Pharmacol; 1994 Mar; 111(3):866-72. PubMed ID: 7912629
[TBL] [Abstract][Full Text] [Related]
20. Enhanced adenylate cyclase activity of turkey erythrocytes following treatment with beta-adrenergic receptor antagonists.
Peters JR; Nambi P; Sibley DR; Lefkowitz RJ
Eur J Pharmacol; 1984 Dec; 107(1):43-52. PubMed ID: 6151904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
